DARA BioSciences, Inc. Regains Compliance With NASDAQ $1.00 Minimum Bid Price Rule

RALEIGH, N.C.--(BUSINESS WIRE)--DARA BioSciences, Inc. (NASDAQ: DARA), a specialty pharmaceutical company focused on oncology and oncology support products (the “Company”), announced today that on October 1, 2012, NASDAQ notified the Company that it has regained compliance Rule 5550(a)(2), which requires a minimum bid price of $1.00 for continued listing on the NASDAQ Stock Market (the “Minimum Bid Price Rule”).